
Study finds patients injected with iPSC-derived heart muscle cells outperform control group on cardiac function tests after bypass surgery
Nanjing Drum Tower Hospital reports that 90% of severe heart failure patients treated with iPSC-derived heart muscle cells showed improved cardiac function at 12 months compared to a control group, according to a phase 2 study published in Nature Medicine.

















